RhumbLine Advisers’s Albany Molecular Research Inc AMRI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-48,218
| Closed | -$1.05M | – | 2921 |
|
|
2017
Q2 | $1.05M | Sell |
48,218
-828
| -2% | -$15K | ﹤0.01% | 1935 |
|
|
2017
Q1 | $688K | Buy |
49,046
+12,478
| +34% | +$204K | ﹤0.01% | 2112 |
|
|
2016
Q4 | $686K | Sell |
36,568
-546
| -1% | -$9.28K | ﹤0.01% | 2054 |
|
|
2016
Q3 | $613K | Buy |
37,114
+250
| +0.7% | +$3.7K | ﹤0.01% | 2083 |
|
|
2016
Q2 | $495K | Buy |
36,864
+4,028
| +12% | +$58.8K | ﹤0.01% | 2201 |
|
|
2016
Q1 | $502K | Buy |
32,836
+260
| +0.8% | +$4.08K | ﹤0.01% | 2220 |
|
|
2015
Q4 | $647K | Buy |
32,576
+825
| +3% | +$15.7K | ﹤0.01% | 2083 |
|
|
2015
Q3 | $553K | Buy |
31,751
+1,078
| +4% | +$21.9K | ﹤0.01% | 2160 |
|
|
2015
Q2 | $620K | Sell |
30,673
-9,035
| -23% | -$174K | ﹤0.01% | 2196 |
|
|
2015
Q1 | $699K | Buy |
39,708
+700
| +2% | +$11.9K | ﹤0.01% | 2087 |
|
|
2014
Q4 | $635K | Buy |
39,008
+730
| +2% | +$13.4K | ﹤0.01% | 2127 |
|
|
2014
Q3 | $845K | Buy |
38,278
+740
| +2% | +$15.2K | ﹤0.01% | 1872 |
|
|
2014
Q2 | $755K | Buy |
37,538
+4,038
| +12% | +$68.4K | ﹤0.01% | 2010 |
|
|
2014
Q1 | $623K | Sell |
33,500
-1,140
| -3% | -$15.7K | ﹤0.01% | 2071 |
|
|
2013
Q4 | $349K | Sell |
34,640
-2,150
| -6% | -$26K | ﹤0.01% | 2494 |
|
|
2013
Q3 | $474K | Sell |
36,790
-205
| -0.6% | -$2.52K | ﹤0.01% | 2245 |
|
|
2013
Q2 | $439K | Buy |
+36,995
| New | +$401K | ﹤0.01% | 2352 |
|
Other funds holding AMRI
RhumbLine Advisers's AMRI Position: Q3 2017 in Review
RhumbLine Advisers sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 48,218 shares — an estimated $1.05M sold.
RhumbLine Advisers first reported a position in AMRI in Q2 2013 and held it in 17 quarters. The position peaked at $1.05M in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.
- RhumbLine Advisers reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
- RhumbLine Advisers sold 48,218 Albany Molecular Research Inc shares in Q3 2017, an estimated $1.05M.
- RhumbLine Advisers first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 17 quarters.
- RhumbLine Advisers's Albany Molecular Research Inc position peaked at $1.05M in Q2 2017.
- 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.
Based on RhumbLine Advisers's 13F filing for Q3 2017, filed 6 Nov 2017.